贝伐珠单抗治疗早产儿视网膜病变的剂量递减研究:晚期复发与追加治疗
这项掩蔽、多中心、剂量递减研究纳入61例1型ROP早产儿,研究眼分别接受0.25、0.125、0.063或0.031 mg贝伐珠单抗玻璃体腔注射。25只研究眼(41%)接受追加治疗,包括早期失败、晚期复发和持续无血管视网膜;6个月矫正年龄时56只研究眼ROP消退且后极部正常。
要点
- 25只研究眼(41%)接受追加治疗,其中晚期复发11只(18%)、持续无血管视网膜11只(18%)。
- 早期失败或晚期复发的再治疗率:0.25 mg组2/11(18%)、0.125 mg组4/16(25%)、0.063 mg组8/24(33%)、0.031 mg组0/10(0%)。
- 6个月矫正年龄时56/61只研究眼ROP消退且后极部正常,1只研究眼发生5期视网膜脱离。
核心结论
- 低剂量贝伐珠单抗治疗ROP后视网膜结构结局很好,尽管许多眼接受了追加治疗。
研究设计与样本
- 掩蔽、多中心、剂量递减研究,纳入61例1型ROP早产儿。
- 若入组时1型ROP为双侧,则随机选择研究眼;研究眼接受0.25 mg、0.125 mg、0.063 mg或0.031 mg贝伐珠单抗玻璃体腔注射;对侧眼必要时接受高一个剂量水平的注射:分别为0.625 mg、0.25 mg、0.125 mg或0.063 mg。
- 4周后追加治疗由研究者决定。
主要发现
- 61只研究眼中25只(41%;95%CI 29%-54%)接受追加治疗:3只(5%;95%CI 1%-14%)为早期失败(4周内),11只(18%;95%CI 9%-30%)为ROP晚期复发(4周后),11只(18%;95%CI 9%-30%)为持续无血管视网膜。
- 早期失败或晚期复发的再治疗率:0.25 mg组2/11(18%;95%CI 2%-52%),0.125 mg组4/16(25%;95%CI 7%-52%),0.063 mg组8/24(33%;95%CI 16%-55%),0.031 mg组0/10(0%;95%CI 0%-31%)。
- 6个月矫正年龄时,61只研究眼中56只ROP消退且后极部正常,1只研究眼发生5期视网膜脱离,4例婴儿死于既存医学状况。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intravitreal bevacizumab is increasingly used to treat severe retinopathy of prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter development of other organs. Previously we reported short-term outcomes of 61 infants enrolled in a dose de-escalation study, and we report the late recurrences and additional treatments. DESIGN: Masked, multicenter, dose de-escalation study. PARTICIPANTS: A total of 61 premature infants with type 1 ROP. METHODS: If type 1 ROP was bilateral at enrollment, then the study eye was randomly selected. In the study eye, bevacizumab intravitreal injections were given at de-escalating doses of 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg; if needed, fellow eyes received 1 dose level higher: 0.625 mg, 0.25 mg, 0.125 mg, or 0.063 mg, respectively. After 4 weeks, additional treatment was at the discretion of the investigator. MAIN OUTCOME MEASURES: Early and late ROP recurrences, additional treatments, and structural outcomes after 6 months. RESULTS: Of 61 study eyes, 25 (41%; 95% confidence interval [CI], 29%-54%) received additional treatment: 3 (5%; 95% CI, 1%-14%) for early failure (within 4 weeks), 11 (18%; 95% CI, 9%-30%) for late recurrence of ROP (after 4 weeks), and 11 (18%; 95% CI, 9%-30%) for persistent avascular retina. Re-treatment for early failure or late recurrence occurred in 2 of 11 eyes (18%; 95% CI, 2%-52%) treated with 0.25 mg, 4 of 16 eyes (25%; 95% CI, 7%-52%) treated with 0.125 mg, 8 of 24 eyes (33%; 95% CI, 16%-55%) treated with 0.063 mg, and 0 (0%; 95% CI, 0%-31%) of 10 eyes treated with 0.031 mg. By 6 months corrected age, 56 of 61 study eyes had regression of ROP with normal posterior poles, 1 study eye had developed a Stage 5 retinal detachment, and 4 infants had died of preexisting medical conditions. CONCLUSIONS: Retinal structural outcomes are very good after low-dose bevacizumab treatment for ROP, although many eyes received additional treatment.
引用
- Wallace DK, Dean TW, Hartnett ME, et al. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology. 2018. PMID: 29887334. doi:10.1016/j.ophtha.2018.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。